MedPath

Prognostic Markers of Post-Stroke Depression (PROMoSD)

Recruiting
Conditions
Acute Ischemic Stroke
Interventions
Diagnostic Test: Transcranial sonography.
Registration Number
NCT05580198
Lead Sponsor
Ruhr University of Bochum
Brief Summary

Single-center prospective observational study investigating the association of brainstem raphe hypoechogenicity detected by transcranial sonography and post-stroke depression three months after an acute ischemic stroke.

Detailed Description

Post-stroke depression (PSD) is an important complication after a stroke. Despite significant limitations between studies of PSD risk factors, stroke severity or post-stroke disability, prior depressive episodes, and female sex are arguably the most well-known risk factors for developing PSD, although the predictive value of these factors is limited.

A hypoechogenic brainstem raphe (BR) detected by transcranial sonography (TCS) is associated with depressive symptoms in distinct diseases but is also common with approximately 25% of the non-depressed population in Europe. The primary aim of this study is to investigate the association between BR hypoechogenicity and PSD occurrence in a prospective observational study design.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
105
Inclusion Criteria
  • Acute ischemic stroke with the onset of symptoms within the past 14 days
  • Diagnosis of AIS is confirmed by brain imaging, either computer tomography or magnetic resonance imaging
Exclusion Criteria
  • Insufficient transtemporal bone window for transcranial sonography examination

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
BRH+Transcranial sonography.Acute ischemic stroke patients with brainstem raphe hypoechogenicity.
BRH-Transcranial sonography.Acute ischemic stroke patients without brainstem raphe hypoechogenicity.
Primary Outcome Measures
NameTimeMethod
Post-stroke depression3 months

PSD diagnosis was defined according to the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V criteria) or by any new medication for anti-depressive indication during follow-up

Secondary Outcome Measures
NameTimeMethod
Severity of depressive symptoms3 months

Measured by the Hamilton Depression Rating Scale (HRSD, minimum score: 0, maximum score: 52), with higher scores indicating greater severity of depressive symptoms.

Trial Locations

Locations (1)

St. Josef-Hospital Bochum

🇩🇪

Bochum, Nordrhein-Westfalen, Germany

© Copyright 2025. All Rights Reserved by MedPath